Appendix 4D and Interim Consolidated Financial Report
Filed with ASX · · 31 pages · English
Attached is Adherium Limited’s Appendix 4D and Interim Consolidated Financial Report for the period to 31 December 2015. An explanation of results for the period is set out in the Director’s report within the Interim Consolidated Financial Report. Rob Turnbull CFO & Joint Company Secretary Company Overview Adherium is a global leader in digital health technologies which address sub optimal medicat
Earlier from Adherium
- Adherium Smartinhaler Technology in Multinational Study
- New Clinical Data Presented at ERS 2015
- Admission to Official List
Later from Adherium
- Clearance to Market in Canada for Flagship Products
- Adherium Smartinhaler in AstraZeneca COPD Study
- Adherium Executes Placement to Fidelity International
- Adherium and AstraZeneca Australia Commercial Pilot Program
- Key Technology Patent Granted in US
Follow Adherium into a list and get an email when it puts out news.
Follow Adherium